SCHEMBL18983192

SCHEMBL18983192

CC(Oc1ccc(C=CC(=O)c2nccs2)cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.43
LMNA P02545 1/20 0.42
SNCA P37840 1/20 0.42
PKM P14618 2/20 0.42
CYP1A2 P05177 2/20 0.42
GAA P10253 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 5/20 0.41
MAPT P10636 4/20 0.41
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 3/20 0.41
TP53 P04637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16686072 1.00 GCK (0.43) GCKLMNASNCAPKMCYP1A2
SCHEMBL18153585 0.79 KMT2A (0.53) LMNAKMT2AMAPTKDM4EMEN1
SCHEMBL16685494 0.79 KMT2A (0.53) LMNAKMT2AMAPTKDM4EMEN1
SCHEMBL20112821 0.78 MAPT (0.54) CYP1A2GAACYP2C9CYP2C19KMT2A
SCHEMBL15525568 0.78 KMT2A (0.58) LMNAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL15525567 0.78 KMT2A (0.58) LMNAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL18983184 0.77 XDH (0.48) LMNAPKMGAAKMT2AMAPT
SCHEMBL16685883 0.77 XDH (0.48) LMNAPKMGAAKMT2AMAPT
SCHEMBL16696289 0.76 PTGS2 (0.54) SNCAPKMCYP1A2CYP2C19KMT2A
SCHEMBL18165781 0.75 NPC1 (0.44) LMNASNCAPKMGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3267995-B1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS UNIV CASE WESTERN RESERVE (US) 2025-10-08 EP disclosed
US-20250295640-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2025-09-25 US disclosed
US-20240100026-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH UNIVERSITY OF IOWA RESEARCH FOUNDATION 2024-03-28 US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20210283113-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2021-09-16 US disclosed
US-20210106587-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY UNIV CASE WESTERN RESERVE (US) 2021-04-15 US disclosed
US-20210100778-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH THE UNIVERSITY OF IOWA 2021-04-08 US disclosed
US-10945998-B2 Inhibitors of short-chain dehydrogenase activity for treating fibrosis CASE WESTERN RESERVE UNIVERSITY (US) 2021-03-16 US disclosed
US-10869871-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2020-12-22 US disclosed
US-20190275014-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING CELL DEATH CASE WESTERN RESERVE UNIVERSITY (US) 2019-09-12 US disclosed
EP-3057973-B1 COMPOSITIONS COMPRISING A 15-PGDH INHIBITOR FOR THE HEALING OF WOUNDS UNIV CASE WESTERN RESERVE (US) 2019-09-04 EP disclosed
EP-3484473-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH Case Western Reserve University (US) 2019-05-22 EP disclosed
US-20180064694-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2018-03-08 US disclosed
WO-2018017582-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH CASE WESTERN RESERVE UNIVERSITY (US) 2018-01-25 WO disclosed
US-9789116-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2017-10-17 US disclosed
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS GCK 1130/4885LMNA 1481/4885SNCA 3966/4885
US-20240100026-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH HPGD, GCDH, DCX GCK 2234/4885LMNA 1628/4885SNCA 1823/4885
US-20210100778-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH HPGD, GCDH, DCX GCK 2234/4885LMNA 1628/4885SNCA 1823/4885
US-20210106587-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS GCK 1130/4885LMNA 1481/4885SNCA 3966/4885
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity HPGD, GCDH, HPGDS GCK 1130/4885LMNA 1481/4885SNCA 3966/4885
US-10869871-B2 Compositions and methods of modulating short-chain dehydrogenase activity HPGD, GCDH, HPGDS GCK 1130/4885LMNA 1481/4885SNCA 3966/4885
US-20190275014-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING CELL DEATH HPGD, DCX, GCDH GCK 2177/4885LMNA 1909/4885SNCA 2281/4885
US-20180064694-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH GCK 1946/4885LMNA 1656/4885SNCA 4265/4885
US-20250295640-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH GCK 1946/4885LMNA 1656/4885SNCA 4265/4885
US-20210283113-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH GCK 1946/4885LMNA 1656/4885SNCA 4265/4885
US-10945998-B2 Inhibitors of short-chain dehydrogenase activity for treating fibrosis GCDH, HPGD, UGDH GCK 1946/4885LMNA 1656/4885SNCA 4265/4885
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS GCK 1130/4885LMNA 1481/4885SNCA 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.